Targets › BLM
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Dec 2026.
ATP-dependent DNA helicase that unwinds double-stranded (ds)DNA in a 3'-5' direction. Participates in DNA replication and repair. (UniProt, P54132)
Open in Phaseline: the race on BLM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | Bleomycin DNA-damaging antibiotic with sclerosing properties | BLM | Phase 2 | Lymphatic Malformation | Dec 2026 |
Lymphatic Malformation (1)
small molecule (1)
West China Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.